Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept for Acute Thyroid Eye Disease
NCT04311606Phase 2Terminated
- Sponsor
- Massachusetts Eye and Ear
- Start
- Nov 2020
- Primary completion
- Dec 2024
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised trial of aflibercept in thyroid eye disease (TED) (3 arms), sponsored by Massachusetts Eye and Ear. Primary endpoint: Adverse Events at Day 45. Started Nov 2020; status: terminated.
02
Drugs
aflibercept
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT04311606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04311606.